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Abstract
Cancer is a leading cause of death of men and women worldwide. Tumor cell motility contributes to metastatic invasion
that causes the vast majority of cancer deaths. Extracellular receptors modified by a2,3-sialic acids that promote this motility
can serve as ideal chemotherapeutic targets. For example, the extracellular domain of the mucin receptor podoplanin
(PDPN) is highly O-glycosylated with a2,3-sialic acid linked to galactose. PDPN is activated by endogenous ligands to induce
tumor cell motility and metastasis. Dietary lectins that target proteins containing a2,3-sialic acid inhibit tumor cell growth.
However, anti-cancer lectins that have been examined thus far target receptors that have not been identified. We report
here that a lectin from the seeds of Maackia amurensis (MASL) with affinity for O-linked carbohydrate chains containing sialic
acid targets PDPN to inhibit transformed cell growth and motility at nanomolar concentrations. Interestingly, the biological
activity of this lectin survives gastrointestinal proteolysis and enters the cardiovascular system to inhibit melanoma cell
growth, migration, and tumorigenesis. These studies demonstrate how lectins may be used to help develop dietary agents
that target specific receptors to combat malignant cell growth.
Citation: Ochoa-Alvarez JA, Krishnan H, Shen Y, Acharya NK, Han M, et al. (2012) Plant Lectin Can Target Receptors Containing Sialic Acid, Exemplified by
Podoplanin, to Inhibit Transformed Cell Growth and Migration. PLoS ONE 7(7): e41845. doi:10.1371/journal.pone.0041845
Editor: Jonas Fuxe, Karolinska Institute, Sweden
Received November 16, 2011; Accepted June 29, 2012; Published July 23, 2012
Copyright: ß 2012 Ochoa-Alvarez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by funding from the NIH (R01CA126897) to J-GG, the Ministry of Education, Culture, Sports, Science and Technology of Japan
to TS, and the Research Foundation of UMDNJ, the Northarvest Bean Growers Association, and Sentrimed to GSG. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Dr. Goldberg and Dr. Temiakov are scientific advisors and shareholders of Sentrimed, which has funded part of this work and supplied the
reagent MASL. Dr. McNulty is an employee of GlaxoSmithKline. There are no patents, products in development or marketed products to declare. This does not
alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: gary.goldberg@umdnj.edu
. These authors contributed equally to this work.

example, we have reported that Src utilizes the focal adhesion
adaptor protein Cas to induce PDPN expression in order to
promote tumor cell migration [15]. PDPN regulates the activities
of effectors including ezrin, Rho, and Cdc42 to mediate filopodia
formation and promote tumor cell migration, invasion, and
metastasis [5,18–22].
PDPN is found at the invasive front of many tumors, which is
consistent with its role in promoting malignant invasion [5,20,23].
For example, PDPN expression is strongly induced in about 40%
of breast cancers [20,24], 50% of oral cancers [23,25,26], and
80% of skin cancers [27,28]. The bulk of the PDPN protein, about
150 amino acids, lies outside of the cell and could serve as an ideal
target to combat cancer invasion and metastasis [5,29].
The extracellular domain of PDPN is highly O-glycosylated with
sialic acid, a2,3 linked to galactose [5,30]. PDPN is activated by

Introduction
Over 1 in 4 people are diagnosed with cancer at some point in
their life [1]. These cancers are the leading cause of death of men
and women under 85 years old [2]. Tumor cell motility contributes to metastatic invasion that causes the vast majority of
cancer deaths [3,4]. Extracellular receptors that promote this
motility can serve as ideal chemotherapeutic targets [5–9]. Expression levels of receptors with a2,3-sialic acid residues are closely
associated with the invasive and metastatic potential of many
cancers [10–12] including skin cancer [13,14]. Podoplanin (PD
PN) represents one of these receptors.
PDPN is a unique transmembrane receptor that promotes
tumor cell motility. PDPN expression can be induced by tumor
promoters including TPA, oncogenic Ras, and Src [15–17]. For
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sialic acid [51,52]. These observations led us to investigate the
ability of MASL to target PDPN on transformed cells.
As shown in Figure 2a, MASL associated with PDPN on the
membrane of Src transformed cells. Note that MASL did not
target the membrane of cells that did not express PDPN, which,
along with functional studies described below, attests to its preferential targeting. In addition, MASL associated with PDPN in
lysates from transformed cells during affinity precipitation experiments as shown in Figure 2b.

endogenous ligands that bind to these extracellular carbohydrate
moieties [31–33] to induce tumor cell motility and metastasis
[20,33–35]. Thus, blocking this interaction should inhibit malignant progression. For instance, compounds blocking the action of
galectins, which activate mucin receptors, can inhibit tumor cell
metastasis [36,37].
Antibodies against PDPN can inhibit lung metastasis of transformed cells that express PDPN [38,39]. However, antibody
therapy presents challenges in administration and toxicity [40,41].
Since PDPN is modified by a2,3-sialic acid, it can be targeted by
specific lectins [10,12–14,42].
Unlike antibodies, lectins can survive digestive processing and
retain biological activity [43–46]. Indeed, dietary lectins can block
the action of endogenous pro-metastatic lectins (such as galectins
or selectins) to inhibit tumor cell growth [37,45–47]. For example,
although its targets and mechanisms are not yet defined, Mistletoe
lectin (viscumin) binds proteins containing a2,3-sialic acid, has
undergone successful clinical trials, and is widely used to treat
melanoma in Europe [48–50]. However, anti-cancer lectins that
have been examined thus far target receptors that have not been
identified.
Here, we show that a lectin with affinity for O-linked carbohydrate chains containing sialic acid binds to PDPN to inhibit
transformed cell growth and motility at submicromolar concentrations. This approach demonstrates how lectins may be used as
dietary agents that target specific receptors to combat malignant
cell growth.

MASL inhibits Src transformed cell growth and migration
We hypothesized that binding of MASL to PDPN would inhibit
transformed cell migration. As shown in Figure 2c, MASL significantly inhibited transformed cell migration, with 385 nM and
770 nM inhibiting cell migration by over 25% and 50%
respectively. In contrast, MASL did not inhibit the migration of
nontransformed cells in a dose dependent fashion at these concentrations.
To verify the functional relevance of MASL targeting PDPN on
cell migration, we investigated its effects on nontransformed cells
transfected with PDPN or empty parental vector. Since PDPN
expression is sufficient to promote cell migration [5,15,30], nontransformed cells transfected with PDPN migrated several fold
more than control transfectants (Figure 3a and 3b). In addition,
MASL reduced the migration of these nontransformed PDPN
transfected cells in a dose dependent fashion (Figure 3b). For
example, 385 nM MASL decreased the migration of PDPN
transfectants by over 40%.
As shown in Figure 3c, in addition to inhibiting cell migration,
MASL was also toxic to PDPN expressing cells in a dose dependent fashion. In contrast, MASL did not inhibit the viability of
empty vector transfectants in an equally dose dependent fashion.
For example, 1540 nM MASL decreased Trypan blue exclusion of
PDPN transfectants by over 70%, but control transfectants by only
about 30%.

Results
MASL targets PDPN on Src transformed cells
We have recently reported that the Src tyrosine kinase utilizes
the adaptor protein Cas/BCAR1 to augment PDPN expression in
order to promote tumor cell motility [15]. PDPN is also profoundly involved in the ability of transformed cells to escape
contact normalization (growth control by surrounding nontransformed cells) and ‘‘break out’’ of their microenvironment to
become malignant or metastatic [15]. Consistent with these previous reports, Src transformed cells expressed more PDPN (see
Figure 1a and 1b) and migrated more than nontransformed
controls (Figure 1c). As described above, the extracellular domain
of PDPN is O-glycosylated with sialic acid, a2,3 linked to galactose. Scholl et al have reported that PDPN associates with lectin
from seeds of the legume tree Maackia amurensis (MASL) [30],
which has an affinity for O-linked carbohydrate chains containing

MASL targets PDPN to inhibit melanoma cell growth and
motility
Studies indicate that PDPN expression is strongly induced in
about 80% of skin cancers [27,28]. Consistent with its role in
tumor cell invasion and metastasis, malignant B16 melanoma cells
expressed higher levels of PDPN (Figure 4a) and migrated
significantly better (Figure 4b) than syngeneic nontransformed
Melan-a melanocytes. As shown in Figure 4c, MASL effectively
suppressed melanoma cell migration at concentrations of 308 nM

Figure 1. Src activation induces Pdpn expression and cell migration. (a) PDPN, active Src kinase (phosphorylated at Y-416), and b-actin were
detected by Western blotting of protein (20 mg per lane) from LA-25 cells (NRK cells containing temperature sensitive v-Src) grown overnight at 33uC
(permissive temperature) or 40uC (non-permissive temperature). (b) PDPN, active Src (phosphorylated at Y416), and b-actin were detected by Western
blotting of protein (15 mg per lane) from nontransformed cells or Src transformed mouse embryonic cells (MEFs) as indicated. (C) Wound healing
migration assays were performed on confluent monolayers of Src transformed or nontransformed cells. Data are shown as the number of cells that
migrated into a 3006300 micron area along the center of the wound in 24 hours (mean + SEM, n = 7). Double asterisks indicate p,0.01 compared to
untreated Src controls.
doi:10.1371/journal.pone.0041845.g001
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Figure 2. MASL associates with PDPN and inhibits migration of Src transformed cells. (a) Src transformed cells were exposed to MASL
conjugated to HiLyte Fluor TR (red), and PDPN was detected by immunofluorescence microscopy (green). Colocalization of lectin and PDPN (yellow)
is apparent in merged images, including orthogonal views of the z-axis which is 14 microns thick (bar = 20 microns). (b) Protein from Src transformed
cells (750 mg) was precipitated with agarose beads linked to MASL, or control beads, and examined for PDPN by Western blotting. Cell lysate (15 mg/
lane) were also examined as indicated. (c) Wound healing migration assays were performed on confluent monolayers of cells treated with
concentrations of MASL as indicated. Data are shown as the number of cells that migrated into a 300x300 micron area along the center of the wound
in 24 hours (mean + SEM, n = 7). Double asterisks indicate p,0.01 compared to nontransformed cells.
doi:10.1371/journal.pone.0041845.g002

or less. In addition to inhibiting melanoma cell migration, MASL
also inhibited melanoma cell growth in a dose responsive manner
(Figure 4d). Moreover, MASL was significantly more toxic to
B16 melanoma cells than Melan-a cells (p,0.001 by ANOVA).
Transwell chambers were used to further investigate the effects
of MASL on melanoma cell growth and migration. As shown in
Figure 4e, while 385 nM MASL was not significantly toxic to
B16 melanoma cells (p.0.2 compared to controls), migration
through 8 micron pores was decreased by over 40 fold. These data
indicate that MASL suppressed melanoma cell migration prior to
inhibiting cell viability.
We employed siRNA to verify the effects of PDPN and MASL
on melanoma cell growth and migration. PDPN siRNA effectively
decreased B16 Pdpn expression levels (Figure 5a) and cell
migration (Figure 5b). As shown in Figure 5c, this decreased
PDPN expression resulted in a 25% decrease in MASL toxicity.
These data indicate that while PDPN may not be the only receptor
targeted by MASL on these melanoma cells, it is a functionally
relevant receptor that can be targeted to prevent melanoma cell
growth and migration.

MASL may induce caspase independent necrosis of
melanoma cells
Some lectins used as potential anticancer agents, including Mistletoe lectins, contain a distinct N-glycosidase motif that acts as a
ribosome inactivating peptide (RIP) [45]. Since MASL does not
contain this peptide, inhibition of tumor cell viability by MASL
did not result from RIP activity. In general, cell death can occur by
apoptosis, necrosis, or autophagy [53,54]. MASL did not induce
characteristics of autophagy such vacuolarization or the formation
of autophagosomes, or characteristics of apoptosis including nuclear chromatin condensation, membrane blebbing, or chromosomal DNA fragmentation. Instead, MASL induced morphological changes typical of necrosis including cell swelling, membrane
rupture, and nuclei fragmentation.
Apoptosis usually results from the induction of caspase activity
which cleaves poly(ADP-ribose) polymerase (PARP) into an 89 kD
fragment [55,56]. As shown in Figure 6, while PARP cleavage
was clearly detected in cells treated with puromycin which induces
caspase mediated apoptosis [57], only slight PARP cleavage was
seen in melanoma cells treated with MASL (p.0.2 by ANOVA).

Figure 3. MASL targets PDPN to decrease cell migration and viability. (a) PDPN and b-actin were detected by Western blotting of protein
(15 mg per lane) from nontransformed mouse embryonic cells (MEFs) transfected with cDNA encoding PDPN or empty parental vector (EF4) as
indicated. (b) Wound healing migration assays were performed on confluent monolayers treated with concentrations of MASL as indicated. Data are
shown as the number of cells that migrated into a 3006300 micron area along the center of the wound in 24 hours (mean + SEM, n = 7). (c) MASL
toxicity was evaluated by Trypan blue staining of cells, and shown as the percent of live cells from each well (mean + SEM, n = 4). Single and triple
asterisks indicate p,0.05 and p,0.001, respectively, compared to untreated controls.
doi:10.1371/journal.pone.0041845.g003
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Figure 4. MASL inhibits melanoma cell motility and viability. (a) PDPN and b-actin were detected by Western blotting of protein (15 mg per
lane) from Melan-a melanocytes and B16 melanoma cells. (b) Wound healing migration assays were performed on confluent MelanA and B16
monolayers. Data are shown as the number of cells that migrated into a 4006500 micron area along the center of the wound in 24 hours (mean +
SEM, n = 5). (c) Wound healing migration assays were performed on confluent monolayers treated with MASL as indicated. Data are shown as the
number of cells that migrated into a 4006500 micron area along the center of the wound in 24 hours (mean + SEM, n = 5). (d) Melan-a and B16 cells
were treated with MASL, and cell viability was evaluated by Alamar blue assay. Data are shown as percent of nontreated cells (mean + SEM, n = 2). (e)
Melanoma cell viability and Transwell migration assays were performed on 600,000 cells plated on cell culture inserts containing membranes with an
8 micron pore size in 6-well plates. Cell viability was evaluated by Alamar blue assay and shown as percent of nontreated cells, while Transwell
migration was measured after 24 hours as the percent of cells found on the underside of the membrane (mean + SEM, n = 2). Double and triple
asterisks indicate p,0.01 and p,0.001 compared to corresponding treatments of untreated cells or Melan-a cells in panels d and e, respectively.
doi:10.1371/journal.pone.0041845.g004

mice fed MASL and then examined for its effects on melanoma
cell migration in vitro to determine if this dietary lectin can survive
gastrointestinal proteolysis to remain biologically active in the
circulatory system. As shown in Figure 7, serum from mice fed
100 or 200 mg/kg MASL inhibited melanoma cell migration by
about 30% or over 80% compared to serum from mice fed no
MASL, respectively. These data indicate that dietary administration of MASL can result in biologically relevant levels of
circulating product that are sufficient to inhibit melanoma cell
migration.

These observations suggest that MASL can reduce tumor cell
growth by caspase independent necrotic mechanisms. This property
may be particularly advantageous when applied to malignancies
that resist apoptosis induced by classical cancer agents.

Dietary MASL inhibits melanoma cell migration and
tumorigenesis
As described above, some dietary lectins can survive digestive
processing to combat cancer in vivo [43–46]. Serum was taken from
PLoS ONE | www.plosone.org
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Figure 5. MASL targets PDPN to inhibit melanoma cell growth. (a) PDPN and b-actin were detected by Western blotting of protein (5 mg per
lane) from B16 melanoma cells transfected with control siRNA or siRNA targeted against PDPN, as indicated. (b) Wound healing migration assays
were performed on confluent B16 monolayers transfected with control siRNA or siRNA targeted against PDPN, as indicated. Data are shown as the
number of cells that migrated into a 5006400 micron area along the center of the wound in 24 hours (mean + SEM, n = 4). (c) MASL toxicity was
evaluated by Trypan blue staining of cells, and shown as the percent of live cells from each well (mean + SEM, n = 2). Single, double, and triple
asterisks indicate p,0.05, p,0.01, and p,0.001, respectively, compared to nontransformed cells, untreated Src transformed cells, or control
transfectants as indicated.
doi:10.1371/journal.pone.0041845.g005

As expected, PDPN expression was evident in melanoma cells of
tumors in vivo. As shown in Figure 8b, PDPN expression was
more intense in tumor cells from control animals than animals
treated with MASL. In addition, tumor cells from MASL treated
animals appeared more epithelial in nature, with a relatively
flattened morphology and more restricted PDPN staining than
tumors from untreated animals.

Since MASL, or at least its biological activity, was resistant to
gastrointestinal proteolysis we examined the effects of dietary
MASL on tumor cell growth in vivo. As shown in Figure 8a, oral
administration of 25 mg/kg of MASL once a week inhibited the
subcutaneous growth of melanoma cells in mice by approximately
50% (p,0.05 by ANOVA). Moreover, we found no adverse effects
on mouse health or physiology over the course of these experiments based on animal behavior, weight, and organ analysis
after dissection.

Dietary MASL inhibits the formation of blood channels
lined by melanoma cells
Although its molecular target has not been defined, Mistletoe
lectin is used as an anticancer agent that can reduce tumor
vascularization in vivo [46,58,59]. Aggressive melanoma cells are
known for their ability to form blood vessels lined with tumor cells
by a process referred to as ‘‘vasculogenic mimicry’’ [60]. Interestingly, as shown in Figure 8b and 8c, these blood filled
vascular spaces lined by tumor cells were much smaller and less

Figure 7. Dietary MASL bioactivity survives gastrointestinal
proteolysis to enter the cardiovascular circulatory system and
inhibit melanoma cell migration. Wound healing migration assays
were performed on confluent monolayers of B16 melanoma cells
treated with serum from mice fed MASL to achieve doses of 1, 100 mg/
kg, or 200 mg/kg, or without mouse serum (controls) as indicated. Data
are shown as the number of cells that migrated into a 2006300 micron
area along the center of the wound in 24 hours (mean + SEM, n = 7).
Triple asterisks indicate p,0.001 compared to controls.
doi:10.1371/journal.pone.0041845.g007

Figure 6. Effects of MASL on PARP cleavage. (top) PARP and bactin were examined by Western blotting of protein from B16
melanoma cells treated for 24 hours with MASL or 37 mM puromycin
as indicated. (bottom) Signal was quantitated by image densitometry
(NIH Image) and shown as the percent of cleaved PARP compared to
total PARP (mean + SEM, n = 2).
doi:10.1371/journal.pone.0041845.g006
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numerous in tumors from MASL treated mice than from control
animals.

Human melanoma cells express PDPN and respond to
MASL
We examined cell lines and clinical specimens to further investigate PDPN expression and MASL sensitivity in human melanoma cells. As shown in Figure 9a, PDPN expression was
drastically increased in primary and metastatic melanoma specimens from every patient that we examined. As with mouse melanoma cells, PDPN expression was also much higher in human
melanoma cell lines than normal skin. In addition, as with mouse
cells, MASL significantly suppressed human melanoma cell growth
and migration at concentrations of less than 300 nM (Figure 9b
and 9c). Moreover, as with mouse cells, MASL inhibited human
melanoma cell motility prior to effecting cell growth. For example,
308 nM MASL inhibited HT-144 cell migration by over 10 fold,
but cell growth by less than 40%.

MASL consists of 2 subunits of identical primary amino
acid sequence
Lectins are a complex family of proteins. MASL is a tetramer
formed by 32 kD and 37 kD subunits. The 32 kD subunit is called
Maackia amurensis hemagglutinin (MAH) and the 37 kD subunit is
called Maackia amurensis leukoagglutinin (MAL) or Maackia amurensis
mitogen (MAM) [52,61,62]. LC-MS-MS analysis shown in
Figure 10 indicates that both of these subunits consist of the
same primary amino acid sequence that contains a single cysteine
toward the carboxyl terminal at position 243. Unique molecular
weights and other properties of these subunits are likely due to
specific modifications including asparagine glycosylation and deamidation events. The presence of a cysteine residue in MASL has
been reported for the 37 kD subunit (MAL) [62]. In contrast,
sequences reported for the 32 kD subunit (MAH) do not contain a
cysteine, but contain a serine in its place [52,61,62]. Our finding
that both 32 kD and 37 kD subunits contain this cysteine explains
their dimerization into respective 64 kD and 74 kD subunits.

Discussion
Lectins are promising anticancer agents that can be administered
orally [47,50]. For example, dietary Mistletoe lectin has been shown
to inhibit lymphoma growth in mice and is used as an adjuvant
therapy to treat various forms of cancer in people [43,59]. Plant
lectins are resistant to gastrointestinal proteolysis and breakdown by
gut bacteria. Wang et al have shown that intact and bioactive
peanut agglutinin (PNA) reaches concentrations of approximately
50nM in the serum of people within hours after ingesting 200g of
peanuts [63]. Our data indicate that similar levels of lectin, or its
bioactive digestion products, may be achieved from ingestion of
MASL. These results also indicate that properties of MASL may be
used to help develop reagents to prevent or combat melanoma.
Melanoma cell motility contributes to metastatic invasion that
causes the vast majority of skin cancer deaths [4]. Robust PDPN
expression was found 100% of the 8 melanoma samples examined
from cancer patients in this study (see Figure 9a). These data are
in contrast to previous studies reporting PDPN expression in less
than 20% of spindle cell and other types of melanomas [64,65].
This may be the result of different experimental methods. For
example, the NZ1 antibody used here targets an approximately 12
amino acid epitope in the PDPN PLAG domain with a
dissociation constant (KD) below 1 nM, while antibody used for
these previous studies targets a larger epitope with lower affinity
[66,67]. However, PDPN staining seen in our patient samples may

Figure 8. Dietary MASL inhibits melanoma growth in vivo. (a)
Mice were fed MASL to achieve a dosage of 0 or 25 mg/kg once weekly
(indicated by asterisks) and inoculated subcutaneously with B16
melanoma cells (100,000 cells per mouse on day indicated by arrow).
Tumors were measured daily by caliper, and data is shown as cubic cm
(mean + SEM, n = 4). (b) Tumors were evaluated for PDPN expression by
IHC as indicated (bar = 50 microns). ‘‘bc’’ indicates blood filled vascular
spaces lined by tumor cells. (c) Tumors were examined by hematoxylin
and eosin staining (H&E) to visualize vascularization and morphology.
(c) Tumor vascularization was quantified as the percent of each field
(0.8 mm2) occupied by blood vessels and shown as mean + SEM (n = 7).
doi:10.1371/journal.pone.0041845.g008
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+ SEM, n = 5). (d) HT-144 cells were treated with MASL, and cell viability
was evaluated by Alamar blue assay. Data are shown as percent of
nontreated cells (mean + SEM, n = 2). Single, double, and triple asterisks
indicate p,0.05, p,0.01, and p,0.001 compared to untreated cells,
respectively.
doi:10.1371/journal.pone.0041845.g009

have been due to cancer associated fibroblasts (CAFs), which
would not be distinguished from actual melanoma cells by
Western blotting. Indeed, PDPN expression in CAFs has been
correlated with tumor aggression in cancers including mammary
carcinoma [68] and lung adenocarcinoma [69–71]. In any case,
robust PDPN expression was seen in all of the melanoma cell lines
that we examined, indicating that melanoma cells themselves
express PDPN (see Figures 4 and 9).
Dietary lectins can block the action of endogenous prometastatic lectins (such as galectins or selectins) to inhibit tumor
cell growth, and can be used as medicinal cancer treatments
[37,45–47]. While MASL has been shown to decrease viability of
different types of transformed cells including melanoma [72,73], its
targets and effects on cell migration have not been reported. Our
data indicate that MASL be used to target PDPN in order to
combat tumor cell growth and migration. Consistent with PDPN
acting as a functionally relevant target, these results indicate that
MASL inhibits cell motility prior to inhibiting cell viability. For
example, 308 nM MASL suppressed melanoma cell migration by
over 99%, while inhibiting cell viability by about 20% within the
same time period (see Figure 4).
Although some lectins may nonspecifically bind to many glycoproteins, experiments with cloned Maackia amurensis lectin
indicate that it can accurately target specific glycoproteins expressed by human cells [74,75]. Our data indicate that MASL,
which has a high affinity for O-linked carbohydrate chains containing sialic acid [51,52], targets PDPN to inhibit transformed cell
growth and motility at nanomolar concentrations. Interestingly,
Maackia amurensis has been used as a medicinal plant for several
centuries to treat ailments including cancer in parts of Asia
[76,77]. However, as with many traditional medicines, clinical
efficacy has been hindered by a lack of mechanistic understanding.
Here, we describe how MASL can serve as a potent bioactive
plant medicine that targets PDPN to combat cancer.
PDPN expression is relatively low in most normal cells, and
found predominantly in tissues including retina, kidney podocytes,
lymphatic endothelium, and lung alveolar epithelium [5,78].
Indeed, as shown in Figure 11, PDPN expression in normal
tissues is somewhat similar to that of VEGFR2 which serves as a
useful chemotherapeutic target [79,80]. Interestingly, PDPN and
VEGFR2 are both receptors that promote cell migration and are
suppressed during contact normalization by surrounding nontransformed cells in the microenvironment [15].
Our data demonstrate that MASL targets PDPN to inhibit
tumor cell growth and motility. However, MASL is bound to
target other receptors containing similar sialic acid motifs. In
addition, like other reagents, MASL may produce ‘‘off target’’
effects in a clinical setting. However, lectin pharmacology is
complex and MASL may undergo enzymatic modification to form
bioactive compounds in vivo. For example, although legumes including lentils and peanuts contain significant amounts of agglutinating lectins, their ingestion does not result in toxic platelet
aggregation [50]. Moreover, MASL caused no notable toxic effects
on organ morphology or animal behavior in our studies which
followed mice treated for about 3 weeks. As stated above, Maackia
amurensis has been used as a medicinal plant for several centuries to
treat ailments including cancer in parts of Asia [76,77]. These
treatments would result in oral administration of hundreds of mg

Figure 9. Human melanoma cells express PDPN and respond to
MASL. (a) PDPN was detected by Western blotting of protein (15 mg
per lane) from a variety of human specimens including normal skin,
primary melanoma, melanoma in transit prior to lymph node
metastasis, nodal metastasis, lung metastasis, and three melanoma
cells lines (HT-144, SK-MEL-2, SK-MEL-5). Detection of MAPK and
nonspecific bands by Western blotting and India ink staining of
membranes is also shown to verify equal loading of these samples from
different patients and cell lines. (b) Wound healing migration assays
were performed on confluent HT-144 monolayers treated with MASL as
indicated. Data are shown as the number of cells that migrated into a
4006500 micron area along the center of the wound in 24 hours (mean
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Figure 10. Analysis of MASL protein subunits. (a) MASL from Sigma (lane 1) or Sentrimed (lane 2) was analyzed by reducing and nonreducing
SDS-PAGE. (b) Coomassie stained bands were excised, extracted and digested with trypsin, reduced and alkylated with iodoacetamide, and
sequenced using data dependent acquisition by LC-MS/MS on a Thermo Scientific LTQ Orbitrap XL. All peptides were identical in primary sequence
and contained a single cysteine at residue 243 (bold in figure).
doi:10.1371/journal.pone.0041845.g010

of MASL per dosage, and have not resulted in reports of toxicity
[81]. However, future studies will clearly be needed to further
investigate the potential toxic effects of MASL or other lectins that
may be considered for clinical use.
Taken together, results from this study suggest that lectins
exemplified by MASL could significantly expand our limited
arsenal of targeted cancer treatments, particularly anticancer
agents that can be administered orally. This paradigm may lead to
novel skin cancer treatments, and pave the way to treat other
cancers with elevated PDPN expression levels including breast
[20,24], glioma [21], and oral cancer [25,26]. However, as stated
above, while PDPN served as the model target of this investigation,
other receptors with a2,3-sialic acid residues are increased in
melanoma and a variety of other cancers, and may also be
targeted to some extent by MASL [10,12–14,42].

harboring a temperature sensitive v-Src construct were grown as
described [82]. B16F10, SK-MEL-2, SK-MEL-5, and HT-144
melanoma cells were obtained from ATCC. Melan-a melanocytes
were provided by Richard Niles [83]. Clones were not taken from
any cell lines, thus minimizing potential effects of clonal variation.
To knockdown Pdpn expression in B16 cells, cells were transfected
with 200nM of nontargeting control siRNA (Dharmacon D001810-10-05) or 200nM podoplanin siRNA (Dharmacon L048117-01-0005) with Lipofectamine 2000 (Invitrogen 11668-027)
as described [15]. For some experiments, cells were treated with
MASL (Sigma L8025, Sentrimed MASL) or puromycin (Sigma
P8833).

Western blotting
Human tissue collected by the Honest Broker Program was
excised and flash frozen in liquid nitrogen at the time of excision
during surgery. Western blotting was performed as previously
described [15,84–86]. Protein was resolved by SDS-PAGE, transferred to Immobilon-P membranes (Millipore IH1079562), and
incubated with antisera specific for PDPN (Sigma NZ1 P0085,
Santa Cruz Biotechnology SC23564, or University of Iowa
Developmental Studies Hybridoma Bank 8.1.1), active Src kinase
(Cell Signaling Technology 2101), PARP (Cell Signaling Technology 9542), MAPK (Cell Signaling Technology 9102), or ß-actin
(Sigma A1978). Primary antiserum was recognized by appropriate secondary antiserum conjugated to horseradish peroxidase
and detected using Enhanced Chemiluminescence (Millipore
WBKLS0500 or Thermoscientific 32106). After blotting, mem-

Materials and Methods
Ethics Statement
Use of mice to obtain serum was approved by Committee of
Animal Experiment in Nagoya University Graduate School of
Medicine (Approved ID: 23132). Mouse experimental protocols
were approved by the University of Medicine and Dentistry
School of Osteopathic Medicine Institutional Animal Care and
Use Committee (Approved ID: 10350).

Cell culture
Mouse embryonic cells transfected with v-Src, PDPN, or empty
parental vectors have been previously described [15]. LA25 cells
PLoS ONE | www.plosone.org
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Figure 11. Comparison of Pdpn and Vegfr2 (Kdr) mRNA expression in human tissues. Values from Affymetrix probe sets representing
Pdpn and Vegfr2 are shown as presented on BioGPS (http://biogps.gnf.org).
doi:10.1371/journal.pone.0041845.g011

followed by 1% bovine serum albumin (BSA) in PBS for 30 minutes,
incubated with PDPN antiserum (1:100) overnight at 4uC, washed,
and then labeled with goat anti-syrian hamster IgG conjugated to
Alexa Fluor 488 (Molecular Probes A21110). Cells were visualized
on a Zeiss Axiovert microscope as described [15,85].

branes were stained with India ink to verify equal loading and
transfer.

Immunofluorescence microscopy
Cells (300,000 per dish) were cultured on 35-mm poly-D-lysine–
coated glass-bottomed culture dishes (MatTek P35GC-1.5-14-C) for
24 hours. MASL was conjugated to Hilyte Fluor TR (Anaspec
72052) and incubated with cells for 15 min at 37uC. Cells were fixed
with 2% paraformaldehyde, permeabilized with 0.2% Triton X-100
in PBS for 10 minutes, washed thrice with 0.1% Tween 20 in PBS
PLoS ONE | www.plosone.org

Affinity precipitation
Cells were lysed in lysis buffer (20 mM Tris.Cl pH 7.4, 150 mM
NaCl, 0.5% Triton X-100, 1mM PMSF) on ice for 30 min, clarified
by centrifugation, diluted to 1 mg/ml in PBS supplemented with
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1mM PMSF and 10 mM MgCl2, and incubated with MASL
conjugated to agarose beads, or empty beads as controls (Thermo
Scientific 20501), on ice for 3 hours. Beads were then washed
4 times with PBS, and eluted in SDS-PAGE sample buffer at 95uC
for 5 minutes. Eluted protein was examined along with total cell
lysates by Western blotting.

control medium not fortified with mouse serum, for 24 hours to
assess their effects on cell migration by wound healing assays,
which were quantitated as the number of cells that entered an area
of the wound indicated in Figure Legends as described [15,84,85].
Use of mice to obtain serum was approved by Committee of
Animal Experiment in Nagoya University Graduate School of
Medicine (Approved ID: 23132).

Cell migration and toxicity assays
In vivo tumorigenesis

Cell monolayers were scratched and incubated with MASL for
24 hours to assess cell migration by wound healing assays, which
were quantitated as the number of cells that entered an area of the
wound indicated in Figure Legends as described [15,84,85].
Alamar blue (Invitrogen DAL1025) was added to cells 24 hours
after MASL treatment, and incubated for an additional 8 hours to
assay viability, which was detected by fluorescence measurements
(ex/em 570/600 nm) as directed by the manufacturer (Invitrogen)
in a Tecan GENios microplate fluorescence spectrophotometer.
Cells were also stained with 0.2% trypan blue and counted with a
hemocytometer to evaluate cytotoxicity. For Transwell migration
assays, 600,000 cells were plated in 6-well cluster plates on cell
culture inserts with an 8 micron pore size (Transwell-Clear,
Costar) and grown for 24 hours. Cells were then released
separately from the top of the membrane and the bottom of the
membrane. Transwell migration was then quantitated as the
percent of cells found on the underside of the membrane as described [15]. All experiments were performed on parallel cultures
to control for variations in cell culture conditions.

Mice (C57BL/6) were fed with a 200 mg food pellet containing
MASL to achieve doses of 0 or 25 mg/kg once weekly, starting the
day before subcutaneous inoculation with 100,000 B16 cells in
0.1 ml PBS. Tumor volumes were measured blindly by a trained
physician with a single caliper daily. Mice were sacrificed 18 days
after inoculation and dissected. Tumors were fixed in formalin,
paraffin embedded, sectioned (5 microns), and processed for
hematoxylin/eosin staining or immunohistochemistry to detect
PDPN expression with 8.1.1 monoclonal antibody as described
[15,85,87]. Samples were analyzed on a Zeiss Axiovert microscope
with Axiovision software as described [15,85]. Mouse experimental protocols were approved by the UMDNJ-SOM Institutional
Animal Care and Use Committee (Approved ID: 10350).

MASL mass spectroscopy
MASL subunits were resolved by reducing and nonreducing
SDS-PAGE and stained by Coomassie dye. Bands were then
extracted and digested with trypsin. Extracted protein was reduced
and alkylated with iodoacetamide, and sequenced using data
dependent acquisition by LC-MS/MS on a Thermo Scientific
LTQ Orbitrap XL.

Ex vivo effects of dietary MASL on cell migration
Mice (C57BL/6) were fed with a 200 mg food pellet containing
MASL to achieve doses of 0, 100, or 200 mg/kg 1 hour before
blood was taken from subclavian vein. Blood was allowed to
coagulate 1 hour at room temperature and clarified by centrifugation for 10 minutes at 20,000 g to obtain serum. This serum was
added to cell culture medium (DMEM+10%FBS) to a final
concentration of 20%. B16 cell monolayers were scratched,
washed with DMEM, and then incubated with these media, or

Author Contributions
Conceived and designed the experiments: GSG YS DT RGN SSS JSG.
Performed the experiments: JAO-A HK YS NKA MH DEM HH TH TS
J-GG MK DT RGN GSG SSS. Analyzed the data: JAO-A HK YS MH
DEM TS J-GG DT RGN GSG. Contributed reagents/materials/analysis
tools: J-GG JSG. Wrote the paper: GSG HK JAO-A.

References
13. Shah MH, Telang SD, Shah PM, Patel PS (2008) Tissue and serum alpha 2-3and alpha 2-6-linkage specific sialylation changes in oral carcinogenesis.
Glycoconj J 25: 279–290.
14. Chovanec M, Plzak J, Betka J, Brabec J, Kodet R, et al (2004) Comparative
analysis of alpha2,3/2,6-linked N-acetylneuraminic acid and cytokeratin
expression in head and neck squamous cell carcinoma. Oncol Rep 12: 297–301.
15. Shen Y, Chen CS, Ichikawa H, Goldberg GS (2010) SRC induces podoplanin
expression to promote cell migration. J Biol Chem 285: 9649–9656.
16. Gandarillas A, Scholl FG, Benito N, Gamallo C, Quintanilla M (1997) Induction
of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse
epidermal keratinocytes during carcinogenesis. Mol Carcinog 20: 10–18.
17. Nose K, Saito H, Kuroki T (1990) Isolation of a gene sequence induced later by
tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic
cells (MC3T3-E1) and expressed constitutively in ras-transformed cells. Cell
Growth Differ 1: 511–518.
18. Martin-Villar E, Yurrita MM, Fernandez-Munoz B, Quintanilla M, Renart J
(2009) Regulation of podoplanin/PA2.26 antigen expression in tumour cells.
Involvement of calpain-mediated proteolysis. Int J Biochem Cell Biol 41: 1421–
1429.
19. Navarro A, Perez RE, Rezaiekhaligh MH, Mabry SM, Ekekezie II (2010)
Polarized Migration of Lymphatic Endothelial Cells is Critically Dependent on
Podoplanin Regulation of Cdc42. Am J Physiol Lung Cell Mol Physiol.
20. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, et al (2006) Tumor
invasion in the absence of epithelial-mesenchymal transition: podoplaninmediated remodeling of the actin cytoskeleton. Cancer Cell 9: 261–272.
21. Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, et al (2010) miR29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma.
Genes Chromosomes Cancer 49: 981–990.
22. Martin-Villar E, Fernandez-Munoz B, Parsons M, Yurrita MM, Megias D, et al
(2010) Podoplanin Associates with CD44 to Promote Directional Cell Migration.
Mol Biol Cell 21: 4387–4399.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer
statistics. CA Cancer J Clin 61: 69–90.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al (2008) Cancer statistics, 2008. CA
Cancer J Clin 58: 71–96.
3. Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and
escape mechanisms. Nat Rev Cancer 3: 362–374.
4. Uong A, Zon LI (2010) Melanocytes in development and cancer. J Cell Physiol
222: 38–41.
5. Wicki A, Christofori G (2007) The potential role of podoplanin in tumour
invasion. Br J Cancer 96: 1–5.
6. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, et al (2004) A
unique structure for epidermal growth factor receptor bound to GW572016
(Lapatinib): relationships among protein conformation, inhibitor off-rate, and
receptor activity in tumor cells. Cancer Res 64: 6652–6659.
7. Nelson MH, Dolder CR (2006) Lapatinib: a novel dual tyrosine kinase inhibitor
with activity in solid tumors. Ann Pharmacother 40: 261–269.
8. Bange J, Zwick E, Ullrich A (2001) Molecular targets for breast cancer therapy
and prevention. Nat Med 7: 548–552.
9. Los M, Roodhart JM, Voest EE (2007) Target practice: lessons from phase III
trials with bevacizumab and vatalanib in the treatment of advanced colorectal
cancer. Oncologist 12: 443–450.
10. Cui H, Lin Y, Yue L, Zhao X, Liu J (2011) Differential expression of the
alpha2,3-sialic acid residues in breast cancer is associated with metastatic
potential. Oncol Rep 25: 1365–1371.
11. Wang FL, Cui SX, Sun LP, Qu XJ, Xie YY, et al (2009) High expression of
alpha 2, 3-linked sialic acid residues is associated with the metastatic potential of
human gastric cancer. Cancer Detect Prev 32: 437–443.
12. Inagaki Y, Tang W, Guo Q, Kokudo N, Sugawara Y, et al (2007)
Sialoglycoconjugate expression in primary colorectal cancer and metastatic
lymph node tissues. Hepatogastroenterology 54: 53–57.

PLoS ONE | www.plosone.org

10

July 2012 | Volume 7 | Issue 7 | e41845

Targeting Podoplanin on Transformed Cells

51. Imberty A, Gautier C, Lescar J, Perez S, Wyns L, et al (2000) An unusual
carbohydrate binding site revealed by the structures of two Maackia amurensis
lectins complexed with sialic acid-containing oligosaccharides. J Biol Chem 275,
17541–17548.
52. Van Damme EJ, Van Leuven F, Peumans WJ (1997) Isolation, characterization
and molecular cloning of the bark lectins from Maackia amurensis. Glycoconj J
14: 449–456.
53. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE (2009) Cell death N Engl J
Med 361: 1570–1583.
54. Loos B, Engelbrecht AM (2009) Cell death: a dynamic response concept.
Autophagy 5: 590–603.
55. Nicholson DW (1999) Caspase structure, proteolytic substrates, and function
during apoptotic cell death. Cell Death Differ 6: 1028–1042.
56. Edinger AL, Thompson CB (2004) Death by design: apoptosis, necrosis and
autophagy. Curr Opin Cell Biol 16: 663–669.
57. Theiss C, Mazur A, Meller K, Mannherz HG (2007) Changes in gap junction
organization and decreased coupling during induced apoptosis in lens epithelial
and NIH-3T3 cells. Exp Cell Res 313: 38–52.
58. Pryme IF, Bardocz S, Pusztai A, Ewen SW (1999) The growth of an established
murine non-Hodgkin lymphoma tumour is limited by switching to a
phytohaemagglutinin-containing diet. Cancer Lett 146: 87–91.
59. Pryme IF, Bardocz S, Pusztai A, Ewen SW (2002) Dietary mistletoe lectin
supplementation and reduced growth of a murine non-Hodgkin lymphoma.
Histol Histopathol 17: 261–271.
60. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, et al (1999) Vascular
channel formation by human melanoma cells in vivo and in vitro: vasculogenic
mimicry. Am J Pathol 155: 739–752.
61. Kawaguchi T, Matsumoto I, Osawa T (1974) Studies on hemagglutinins from
Maackia amurensis seeds. J Biol Chem 249: 2786–2792.
62. Yamamoto K, Konami Y, Irimura T (1997) Sialic acid-binding motif of Maackia
amurensis lectins. J Biochem 121: 756–761.
63. Wang Q, Yu LG, Campbell BJ, Milton JD, Rhodes JM (1998) Identification of
intact peanut lectin in peripheral venous blood. Lancet 352: 1831–1832.
64. Buonaccorsi JN, Plaza JA (2012) Role of CD10, Wide-Spectrum Keratin, p63,
and Podoplanin in the Distinction of Epithelioid and Spindle Cell Tumors of the
Skin: An Immunohistochemical Study of 81 Cases. Am J Dermatopathol.
65. Yu H, Pinkus GS, Hornick JL (2007) Diffuse membranous immunoreactivity for
podoplanin (D2-40) distinguishes primary and metastatic seminomas from other
germ cell tumors and metastatic neoplasms. Am J Clin Pathol 128: 767–775.
66. Ogasawara S, Kaneko MK, Price JE, Kato Y (2008) Characterization of antipodoplanin monoclonal antibodies: critical epitopes for neutralizing the
interaction between podoplanin and CLEC-2. Hybridoma (Larchmt.) 27:
259–267.
67. Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, et al (2010)
Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting
malignant gliomas. Nucl Med Biol 37: 785–794.
68. Pula B, Jethon A, Piotrowska A, Gomulkiewicz A, Owczarek T, et al (2011)
Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in
invasive ductal breast carcinoma. Histopathology 59: 1249–1260.
69. Ito M, Ishii G, Nagai K, Maeda R, Nakano Y, et al (2012) Prognostic impact of
cancer-associated stromal cells in stage I lung adenocarcinoma patients. Chest.
70. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, et al (2011) Podoplanin-positive
fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in
fibroblast functions for tumor progression. Cancer Res 71: 4769–4779.
71. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, et al (2008) Podoplanin
expression by cancer associated fibroblasts predicts poor prognosis of lung
adenocarcinoma. Int J Cancer 123: 1053–1059.
72. Wang H, Ng TB, Ooi VE, Liu WK (2000) Effects of lectins with different
carbohydrate-binding specificities on hepatoma, choriocarcinoma, melanoma
and osteosarcoma cell lines. Int J Biochem Cell Biol 32: 365–372.
73. Kapoor S, Marwaha R, Majumdar S, Ghosh S (2008) Apoptosis induction by
Maackia amurensis agglutinin in childhood acute lymphoblastic leukemic cells.
Leuk Res 32: 559–567.
74. Maenuma K, Yim M, Komatsu K, Hoshino M, Tachiki-Fujioka A, et al (2009)
A library of mutated Maackia amurensis hemagglutinin distinguishes putative
glycoforms of immunoglobulin A1 from IgA nephropathy patients. J Proteome
Res 8: 3617–3624.
75. Maenuma K, Yim M, Komatsu K, Hoshino M, Takahashi Y, et al (2008) Use of
a library of mutated Maackia amurensis hemagglutinin for profiling the cell
lineage and differentiation. Proteomics 8: 3274–3283.
76. Fedoreev SA, Kulish NI, Glebko LI, Pokushalova TV, Veselova MV, et al (2010)
Maksar: A preparation based on amur maackia. Pharmaceutical Chemistry
Journal 38: 605–610.
77. Li X, Wang D, Xia MY, Wang ZH, Wang WN, et al (2009) Cytotoxic
prenylated flavonoids from the stem bark of Maackia amurensis. Chem Pharm
Bull (Tokyo) 57: 302–306.
78. Grimaldo S, Garcia M, Zhang H, Chen L (2010) Specific role of lymphatic
marker podoplanin in retinal pigment epithelial cells. Lymphology 43: 128–134.
79. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour
activity. Nat Rev Cancer 8: 579–591.
80. Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Vascular endothelial
growth factor receptor-2: structure, function, intracellular signalling and
therapeutic inhibition. Cell Signal 19: 2003–2012.

23. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, et al
(2005) Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a
small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer
113: 899–910.
24. Kono T, Shimoda M, Takahashi M, Matsumoto K, Yoshimoto T, et al (2007)
Immunohistochemical detection of the lymphatic marker podoplanin in diverse
types of human cancer cells using a novel antibody. Int J Oncol 31: 501–508.
25. Kawaguchi H, El Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, et al
(2008) Podoplanin: a novel marker for oral cancer risk in patients with oral
premalignancy. J Clin Oncol 26: 354–360.
26. Yuan P, Temam S, El Naggar A, Zhou X, Liu DD, et al (2006) Overexpression
of podoplanin in oral cancer and its association with poor clinical outcome.
Cancer 107: 563–569.
27. Liang H, Wu H, Giorgadze TA, Sariya D, Bellucci KS, et al (2007) Podoplanin
is a highly sensitive and specific marker to distinguish primary skin adnexal
carcinomas from adenocarcinomas metastatic to skin. Am J Surg Pathol 31:
304–310.
28. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, et al (2005) Upregulation of the lymphatic marker podoplanin, a mucin-type transmembrane
glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J
Pathol 166: 913–921.
29. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, et al (2007) The
platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary
metastasis. Am J Pathol 170: 1337–1347.
30. Scholl FG, Gamallo C, Vilaro S, Quintanilla M (1999) Identification of PA2.26
antigen as a novel cell-surface mucin-type glycoprotein that induces plasma
membrane extensions and increased motility in keratinocytes. J Cell Sci 112 (Pt
24): 4601–4613.
31. Cueni LN, Detmar M (2009) Galectin-8 interacts with podoplanin and
modulates lymphatic endothelial cell functions. Exp Cell Res 315: 1715–1723.
32. Christou CM, Pearce AC, Watson AA, Mistry AR, Pollitt AY, et al (2008) Renal
cells activate the platelet receptor CLEC-2 through podoplanin. Biochem J 411:
133–140.
33. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, et al (2007)
Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated
platelet activation, by cancer cells. J Biol Chem 282: 25993–26001.
34. Witz IP (2006) The involvement of selectins and their ligands in tumorprogression. Immunol Lett 104: 89–93.
35. Witz IP (2006) Tumor-microenvironment interactions: the selectin-selectin
ligand axis in tumor-endothelium cross talk. Cancer Treat Res 130: 125–140.
36. Ingrassia L, Camby I, Lefranc F, Mathieu V, Nshimyumukiza P, et al (2006)
Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem 13:
3513–3527.
37. Hasan SS, Ashraf GM, Banu N (2007) Galectins – potential targets for cancer
therapy. Cancer Lett 253: 25–33.
38. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, et al (2008) Molecular
analysis of the pathophysiological binding of the platelet aggregation-inducing
factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 99: 54–
61.
39. Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, et al (2008) Tetraspanin
family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation
and suppresses pulmonary metastasis. Blood 112: 1730–1739.
40. Johnson KA, Brown PH (2010) Drug development for cancer chemoprevention:
focus on molecular targets. Semin Oncol 37: 345–358.
41. de Bono JS, Ashworth A (2010) Translating cancer research into targeted
therapeutics. Nature 467: 543–549.
42. Cerna A, Janega P, Martanovic P, Lisy M, Babal P (2002) Changes in sialic acid
expression in the lung during intrauterine development of the human fetus. Acta
Histochem 104: 339–342.
43. Pryme IF, Dale TM, Tilrem P (2007) Oral mistletoe lectins: a case for their use
in cancer therapy. Cancer Therapy 5: 287–300.
44. Beuth J, Schneider B, Schierholz JM (2008) Impact of complementary treatment
of breast cancer patients with standardized mistletoe extract during aftercare: a
controlled multicenter comparative epidemiological cohort study. Anticancer
Res 28: 523–527.
45. Pusztai A, Bardocz S, Ewen SW (2008) Uses of plant lectins in bioscience and
biomedicine. Front Biosci 13: 1130–1140.
46. Pryme IF, Bardocz S, Pusztai A, Ewen SW (2006) Suppression of growth of
tumour cell lines in vitro and tumours in vivo by mistletoe lectins. Histol
Histopathol 21: 285–299.
47. Liu B, Bian HJ, Bao JK (2010) Plant lectins: potential antineoplastic drugs from
bench to clinic. Cancer Lett 287: 1–12.
48. Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B (2005) Safety and
efficacy of the long-term adjuvant treatment of primary intermediate- to highrisk malignant melanoma (UICC/AJCC stage II and III) with a standardized
fermented European mistletoe (Viscum album L.) extract. Results from a
multicenter, comparative, epidemiological cohort study in Germany and
Switzerland. Arzneimittelforschung 55: 38–49.
49. Icirsch A (2007) Successful treatment of metastatic melanoma with Viscum
album extract (Iscador (R) M) J Alternative and Complementary Medicine 13:
443–445.
50. De Mejia EG, Prisecaru VI (2005) Lectins as bioactive plant proteins: a potential
in cancer treatment. Crit Rev Food Sci Nutr 45: 425–445.

PLoS ONE | www.plosone.org

11

July 2012 | Volume 7 | Issue 7 | e41845

Targeting Podoplanin on Transformed Cells

81. (1955) ‘‘llustrated Manual of China Main Plants- the Family Leguminosae,’’
Science Press, Beijing.
82. Crow DS, Kurata WE, Lau AF (1992) Phosphorylation of connexin43 in cells
containing mutant src oncogenes. Oncogene 7: 999–1003.
83. Estler M, Boskovic G, Denvir J, Miles S, Primerano DA, et al (2008) Global
analysis of gene expression changes during retinoic acid-induced growth arrest
and differentiation of melanoma: comparison to differentially expressed genes in
melanocytes vs melanoma. BMC Genomics 9: 478.
84. Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS (2009) Regulation of miRNA
expression by Src and contact normalization: effects on nonanchored cell growth
and migration. Oncogene 28: 4272–4283.

PLoS ONE | www.plosone.org

85. Shen Y, Jia Z, Nagele RG, Ichikawa H, Goldberg GS (2006) SRC uses Cas to
suppress Fhl1 in order to promote nonanchored growth and migration of tumor
cells. Cancer Res 66: 1543–1552.
86. Alexander DB, Ichikawa H, Bechberger JF, Valiunas V, Ohki M, et al (2004)
Normal cells control the growth of neighboring transformed cells independent of
gap junctional communication and SRC activity. Cancer Res 64: 1347–1358.
87. Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, et al (2008) Coordinate suppression of
Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer
Sci 99: 1326–1333.

12

July 2012 | Volume 7 | Issue 7 | e41845

